skip to Main Content

Staphylococcus aureus skin infection model

The increasing rate of bacterial resistance creates a challenging environment for the development of therapies for bacterial infections. Bacterial skin infections are one of the leading manifestations of infectious disease in the world. Staphylococcus aureus—both Methicillin-resistant (MRSA) and Methicillin-Sensitive (MSSA) strains—is the leading cause of skin and soft tissue infections in the USA. It is the leading cause of hospital associated (HA) and community associated (CA) infections worldwide.

Read More

Flow Cytometry: A Vital Tool for Evaluating Vaccine Effectiveness

Flow cytometry uses light scattering, light excitation and emission of fluorochrome molecules to gather detailed information about specific cells or particles of interest. Using antibody-fluorophore conjugates flow cytometry allows researchers to draw phenotype-dependent conclusions about cellular phenotype and function.  The fluorophores present on bound antibodies excited by lasers yield detailed…

Read More

Influenza Hemmagglutination Inhibition Assay

According to WHO statistics, seasonal influenza viruses cause 3-5 million cases of infection with 290,000-650,000 deaths worldwide each year. There are 4 types of seasonal influenza viruses. Types A (which can infect and be transmitted between birds and some mammals such as pigs and humans) and B (which only infects…

Read More

Integrated Biotherapeutics, Inc. @ World Anti-Microbial Resistance Congress 2019

4 November 2019   INTEGRATED BIOTHERAPEUTICS TO PRESENT ON NOVEL VACCINES FOR MRSA AT WORLD ANTI-MICROBIAL CONGRESS 2019   Integrated Biotherapeutics, Inc. @ World Anti-Microbial Resistance Congress 2019   AN INDUSTRY EXPERTS CONFERENCE ON COMBATING ANTI-MICROBIAL RESISTANCE Maryland — 4 November 2019 – Integrated Biotherapeutics CEO Dr. M. Javad Aman will…

Read More

Production of Monoclonal Antibodies

Hybridoma Technology  History Monoclonal antibodies (mAbs) are monovalent (one epitope) antibodies derived from clones of a single parental immune cell. The original method for producing monoclonal antibodies is found in hybridoma technology. Prior to the production of monoclonal antibodies, polyclonal antibodies (multiple epitopes, multiple parental cells) were the standard for…

Read More

Alhydrogel Interference in Immunoassays

Troubleshooting immunoassays for adjuvanted vaccine products The safety record, affordability, and compatibility of aluminum to many antigens makes them a primary choice of adjuvant. Aluminum adjuvant compounds (such as aluminum hydroxide (Al(OH)3) and aluminum phosphate (AlPO4)) help maintain the physical and chemical characteristics of antigens and increase their repository effect…

Read More

Combating Staph aureus superantigen toxins

Superantigen toxins : Of cytokine storms and immune short-circuits -how do we combat the ensuing system blackout ? New research findings [1,2]  suggest that dangerous bacteria Staphylococcus aureus (S. aureus) are no longer able to interact and cause inflammation in target epithelial cells when CD40 specific molecules are genetically removed…

Read More

Prophylaxis and immunotherapy of S. aureus/MRSA disease

Staphylococcus aureus (SA) is a Gram-positive bacterium that colonizes approximately one third of the human population1.  It causes a wide range of diseases from skin and soft tissue infections (SSTI) to life-threatening systemic disease such as bacteremia and pneumonia with high mortality rates2,3.  Currently, methicillin-resistant S. aureus (MRSA) is killing as many people…

Read More

Virus-like Particles: Tools for your infectious disease research

Virus-like particles (VLPs) are non-infectious nanoparticles that assemble from recombinantly expressed viral proteins but lack the viral genome required for replication and infection. Because they are non-infectious VLPs do not require the same level of biosafety containment as competent native viruses but retain the self-assembling and antigen presenting capabilities that…

Read More
Back To Top
×Close search

IBT Bioservices continues to conduct critical work as an essential business under the State of Maryland’s COVID-19 response directive. We have implemented a risk management plan and are continually monitoring the situation to ensure continuation of research according to public health services recommended best-practices for keeping our employees and the community safe. 

The IBT Bioservices team will continue to deliver high quality products and services for every project. If you have any questions contact us at